medigraphic.com
Coordinación General de Investigación de la Facultad de Salud Pública y Nutrición y la Dirección General de Sistemas e Informática de la Universidad Autónoma de Nuevo León

2012, Número 1

<< Anterior

Rev Salud Publica Nutr 2012; 13 (1)


Hipertrofia ventricular en el paciente con obesidad

Haro AME, Arce MA, Ponce PLG, Núñez SA, Ruiz-Esparza CJ, Soria RCG, Clarck OI, Maciel MG

Idioma: Español
Referencias bibliográficas: 50
Paginas:
Archivo PDF: 98.41 Kb.


RESUMEN

La obesidad representa un factor riesgo importante a padecer enfermedades cardiovasculares, en fase temprana se desarrolla hipertrofia ventricular izquierda, la cual representa un factor de riesgo de cardiovascular independiente, en niños como en el adultos. En esta revisión se describen los mecanismos fisiopatológicos que ocasionan la hipertrofia cardiaca.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Organización Mundial de la Salud. 2011. Obesidad y Sobrepeso. Nota descriptive No311. Marzo Obtenido por: http://www.who.int/mediacentre/factsheets

  2. Rana JS, M Nieuwdorp, JW Jukema, JJP Kastelein 2007. Cardiovascular metabolic syndrome – an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes, Obesity and Metabolism; 9:218-232.

  3. Isomaa B, P. Almgren, T. Tuomi , B. Forsen, K Lahti , M Nissen , Taskinen MR, L Groop. 2001. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care; 24:683-689.

  4. Stroke Statistics 2011 Update. A report from the American Heart Association. Circulation 2011, 123: e18-e209.

  5. Principales causas de mortalidad general. 2008 www.sinais.salud.gob.mx

  6. Gibson SH. 2007. A clinical guide to Pediatric weight management and obesity.USA: Lippincott Williams and Wilkins..Cap 7 y 8: 63-103.

  7. Lobstein T, L Baur , R Uauy 2004. Obesity in children and young people: a crisis in public health. Obesity reviews; 5 (1):4-85.

  8. Ho. TF. 2009. Cardiovascular risks associated with obesity in children and adolescents. Ann Acad Med Singapore:38:48-56.

  9. Vázquez-Antona CA. 2007. La prevención primaria de la enfermedad cardiovascular inicia en la infancia. Arch Cardiol Mex,77:7-10.

  10. Vakili BA, PM Okin, RB Devereux 2001. Prognostic implications of left ventricular hypertrophy. Am Heart J, 141: 334-341

  11. Xiangrong L, Shengxu, Ulusoy E, W Chen, SR Srinivasan, GS Berenson 2004. Childhood adiposity as a predictor of cardiac mass in adulthood: the Bogalusa Heart Study. Circulation; 110:3488-3492.

  12. Dietz WH, TN Robinson 2005. Overweight children and adolescents. N Engl J Med; 352:2100-2109.

  13. Daniel SR, DK Arnett, RH Eckel, SS Gidding, LL Hayman, K Shiriki, TN Robinson, BJ Scott, S Jeor, CL Williams 2005. Overweight in children and adolescents. Pathophysiology, consequences, prevention and treatment. Circulation; 111:199-212.

  14. Poirier P, TD Giles, GA Bray, Y Hong, JS Stern, XF Pi-Sunyer, RH Eckel 2006. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. Circulation; 113: 898-918.

  15. Wong CY, T O’Moore-Sullivan, R Leano, N Byrne, E Bellere 2004. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation; 110:3081-3087.

  16. Beverly LH and CA Blasé 2000. Left ventricular hypertrophy: pathogenesis, detection and prognosis. Circulation; 102(4):470-479

  17. Schaub MC, MA Hefti, BA Harder, HM Eppenberger 1997. Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes. J Mol Med; 75: 901-920.

  18. Bertolasi. 2000. En Cardiología. Ed. Panamericana. Argentina 2001. Cap. 41: 3266-3289.

  19. Crawford MH, JP DiMarco. 2002. En: Cardiología. Madrid: Harcout. Cap. 5.1:1-16.

  20. Bertolasi, et al.Op cit.

  21. Crawford MH,et al Op.cit

  22. Best y Taylor. 2003. En: Bases fisiológicas de la práctica médica. 13ª.ed. España: Panamericana. Cap13: 189-211.

  23. Ross, KP 2006. En: Histología. Texto atlas color con biología celular y molecular. 4ed Argentina. Panamericana. Cap. 10:265.

  24. Best y Taylor, et al. Op.cit.

  25. Idem.

  26. Stuart IF. 2003. En: Fisiología Humana. España: Mc Graw Hill. Cap.19:631-632

  27. Gibson SH 2007. A clinical guide to Pediatric weight management and obesity.USA: Lippincott Williams and Wilkins..Cap. 3: 24.

  28. Idem.

  29. Viveros AC, HM Laviada, RS Bastarrachea 2002. Influencia endocrina y paracrina sobre la adipogénesis. Revista de Endocrinología y Nutrición; 10(3) 151-164.

  30. Pou KM, JM Massaro, U Hoffmann, RS Vasan, P Maurovich-Horvat, MG Larson 2007. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress, The Framingham Heart Study. Circulation; 116:1234-1241.

  31. Laycock JF and P Wise 1996 Disorders of lipid metabolism and obesity. En: Laycock JF. Essential Endocrinology.3 Ed. New York: Oxford University Press Inc: 338-352.

  32. Després JP and I Lemieux 2006. Abdominal obesity and metabolic syndrome. Nature; 444 (14): 881-887.

  33. Bastarrachea RA, R Fuentemayor, I Brajkovisch, AG Comuzzie 2005. Entendiendo las causas de la obesidad a través de la biología molecular del adipocito. Revisión. Rev. Venez Endocrinol Metab; 3(3): 20-29.

  34. Poirier P, et al. Op.cit.

  35. Alpert MA, et al. Op.cit.

  36. Tuck ML, J Soers, L Dornfeld, G Kledzik, M Maxwell 1981. The effect of weight reduction on blood pressure, plasma rennin activity, and plasma aldosterone levels in obese patiente. N Engl J Med, 304:930-933

  37. Engeli S, R Negrel, AM Sharma 2000. Physiology and pathophysiology of adipose tissue rennin-angiotensin system. Hypertension, 35:1270-1277.

  38. WongCY, T O¨Moore-Sullivan, R Leano, N Byrne, E Beller, TH Marwick 2004. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation; 110: 3081-3087.

  39. Engeli S, et al. Op.cit.

  40. Di Bello V, F Santini, A Di Cori, A Pucci, C Palagi, MG Dellle, P Fierabracci, A Marsili, E Talini, M Giannetti, O Biadi, A Balbarini, M Mariani, A Pinchera 2006. Obesity cardiomyopathy is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr, 19: 1063-1071.

  41. Keaney JF, MG Larson, RS Varsan, PW Wilson, I Lipinska, D Covey, JM Massaro, P Sutherland, JA Vita, EJ Benjamin 2003. Framinghan Study. Arterioscler Thromb Vasc Biol:23: 434-439.

  42. Barton M 2011. Obesity and aging determinants of endothelial cell dysfunction and atherosclerosis. Eur J Physiol, 460: 829-837.

  43. Balagopal P, SD de Ferranti, S Cook, SR Daniel, SS Gidding, LL Hayman, BW McCrindle, ML Mietus-Snyder, J Steinberger. 2011 AHA Scientific Statement. Circulation; 123: 2749-2769.

  44. López-Jiménez F y M Cortés-Bergoderi 2011. Obesidad y corazón. Rev. Esp. Cardiol; 64 (2): 140-149.

  45. De Simone G, SR Daniels, RB Devereux, RA, RA Meyer, MJ Roman, De Divitiis O, MH Alderman 1992. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. J Am Coll Cardiol; 20:1251-1260.

  46. Daniels SR, TR Kimball, JA Morrison, P Khoury, S Witt, RA Meyer 1995. Effect of lean body mass, fat mass, blood pressure, and sexual maturation on left ventricular mass in children and adolescents. Statistical, biological and clinical significance. Circulation, 92:3249-3254.

  47. Chinali M, G De Simone, MJ Roman, ET Lee, LG Best , BV Howard , RB Devereux 2006. Impact of obesity on cardiac geometry and function in a population of adolescents. J Am Coll Cardiol; 47:2267-2273.

  48. Schaub MC, et al. Op.cit.

  49. Wong C and TH Marwick 2007. Obesity cardiomyopathy: diagnosis and therapeutic implications. Nature; 4 (9): 481-490.

  50. Douglas PS., R.F. Stainback, N.J. Weissman, et al. 2007. ACCF/ ASE/ ACEP/ASNC/SCAI/SCCT/SCMR 2007. Appropriateness Criteria for Transthoracic and Transesophageal Echocardiography. JACC; 50:187-204.




2020     |     www.medigraphic.com